Healthcare - Biotechnology - NASDAQ - US
$ 5.84
-5.96 %
$ 222 M
Market Cap
-3.74
P/E
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc.[ Read More ]
The intrinsic value of one OBIO stock under the base case scenario is HIDDEN Compared to the current market price of 5.84 USD, Orchestra BioMed Holdings, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart OBIO
FINANCIALS
2.76 M
REVENUE
-51.5 M
OPERATING INCOME
-49.1 M
NET INCOME
-46.1 M
OPERATING CASH FLOW
10.7 M
INVESTING CASH FLOW
46.2 M
FINANCING CASH FLOW
987 K
REVENUE
-16.3 M
OPERATING INCOME
-15.4 M
NET INCOME
-13.7 M
OPERATING CASH FLOW
557 K
INVESTING CASH FLOW
15 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Orchestra BioMed Holdings, Inc.
| Current Assets | 89.1 M |
| Cash & Short-Term Investments | 87.6 M |
| Receivables | 99 K |
| Other Current Assets | 1.42 M |
| Non-Current Assets | 6.1 M |
| Long-Term Investments | 2.5 M |
| PP&E | 2.83 M |
| Other Non-Current Assets | 769 K |
| Current Liabilities | 11.2 M |
| Accounts Payable | 2.9 M |
| Short-Term Debt | 1.3 M |
| Other Current Liabilities | 7.01 M |
| Non-Current Liabilities | 16 M |
| Long-Term Debt | 1.04 M |
| Other Non-Current Liabilities | 14.9 M |
EFFICIENCY
Earnings Waterfall
Orchestra BioMed Holdings, Inc.
| Revenue | 2.76 M |
| Cost Of Revenue | 186 K |
| Gross Profit | 2.57 M |
| Operating Expenses | 54.1 M |
| Operating Income | -51.5 M |
| Other Expenses | -2.39 M |
| Net Income | -49.1 M |
RATIOS
93.26%
GROSS MARGIN
-1866.16%
OPERATING MARGIN
-1779.71%
NET MARGIN
-72.19%
ROE
-51.59%
ROA
-74.98%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Orchestra BioMed Holdings, Inc.
| Net Income | -49.1 M |
| Depreciation & Amortization | 287 K |
| Capital Expenditures | -78 K |
| Stock-Based Compensation | 7.62 M |
| Change in Working Capital | -3.31 M |
| Others | -5.19 M |
| Free Cash Flow | -46.2 M |
Wall Street Analysts Price Targets
Orchestra BioMed Holdings, Inc.
OBIO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Orchestra BioMed Holdings, Inc.
Sold
0-3 MONTHS
226 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
47.9 K USD 1
0-3 MONTHS
74.5 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Sep 24, 2024
|
Bought 12.3 K USD
|
Hochman David P
See Remarks |
+ 2500
|
4.91 USD |
|
1 month ago
Sep 25, 2024
|
Bought 7.29 K USD
|
Hochman David P
See Remarks |
+ 1500
|
4.86 USD |
|
1 month ago
Sep 25, 2024
|
Bought 9.48 K USD
|
Hochman David P
See Remarks |
+ 2000
|
4.74 USD |
|
1 month ago
Sep 25, 2024
|
Bought 9.4 K USD
|
Hochman David P
See Remarks |
+ 2000
|
4.7 USD |
|
1 month ago
Sep 25, 2024
|
Bought 9.46 K USD
|
Hochman David P
See Remarks |
+ 2000
|
4.73 USD |
|
2 months ago
Sep 09, 2024
|
Sell 37.3 K USD
|
Sherman Darren
See Remarks |
- 6804
|
5.48 USD |
|
2 months ago
Sep 10, 2024
|
Sell 36.7 K USD
|
Sherman Darren
See Remarks |
- 6904
|
5.31 USD |
|
2 months ago
Sep 06, 2024
|
Sell 11.3 K USD
|
Fain Eric S
Director |
- 2000
|
5.64 USD |
|
2 months ago
Sep 09, 2024
|
Sell 9.77 K USD
|
Fain Eric S
Director |
- 1800
|
5.43 USD |
|
2 months ago
Sep 10, 2024
|
Sell 9.61 K USD
|
Fain Eric S
Director |
- 1800
|
5.34 USD |
|
2 months ago
Sep 04, 2024
|
Sell 41.7 K USD
|
Sherman Darren
See Remarks |
- 6837
|
6.1 USD |
|
2 months ago
Sep 05, 2024
|
Sell 40.7 K USD
|
Sherman Darren
See Remarks |
- 6961
|
5.85 USD |
|
2 months ago
Sep 06, 2024
|
Sell 38.5 K USD
|
Sherman Darren
See Remarks |
- 6819
|
5.65 USD |
|
3 months ago
Aug 14, 2024
|
Bought 14.6 K USD
|
Hochman David P
See Remarks |
+ 2500
|
5.84 USD |
|
4 months ago
Jun 25, 2024
|
Bought 6.95 K USD
|
Hochman David P
See Remarks |
+ 1000
|
6.95 USD |
|
5 months ago
May 30, 2024
|
Bought 28 K USD
|
Little William Reed
See Remarks |
+ 4000
|
7 USD |
|
6 months ago
May 17, 2024
|
Bought 15.5 K USD
|
Hochman David P
See Remarks |
+ 3000
|
5.15 USD |
|
6 months ago
May 16, 2024
|
Bought 9.5 K USD
|
Hochman David P
See Remarks |
+ 2000
|
4.75 USD |
7. News
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.38 per share a year ago.
zacks.com
- 4 days ago
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update.
globenewswire.com
- 4 days ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.35 per share a year ago.
zacks.com
- 3 months ago
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.
globenewswire.com
- 3 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Orchestra BioMed Holdings, Inc. (OBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 3 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 3 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know
Orchestra BioMed Holdings, Inc. (OBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 3 months ago
Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102.6% in Orchestra BioMed Holdings, Inc. (OBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 3 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
- 4 months ago
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 5 months ago
Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?
The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 5 months ago
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.
globenewswire.com
- 5 months ago
8. Profile Summary
Orchestra BioMed Holdings, Inc. OBIO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 222 M
Dividend Yield
0.00%
Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Contact
150 Union Square Drive, New Hope, PA, 18938
https://orchestrabiomed.com
IPO Date
Aug. 4, 2020
Employees
56
Officers
Dr. Yuval Hay Mika D.Sc, Ph.D.
GM & Chief Technology Officer of Bioelectronic Therapies
Dr. George Papandreou Ph.D.
GM & Senior Vice President of Focal Therapies
Mr. Bob Laughner
Senior Vice President of Regulatory & Quality
Mr. Juan Lorenzo
Senior Vice President of Product Development
Dr. Hans-Peter Stoll M.D., Ph.D.
Chief Clinical Officer
Mr. Andrew Lawrence Taylor M.B.A.
Chief Financial Officer
Dr. Avraham Matityahu Fischer M.D.
Senior Vice President of Medical Affairs & Innovation
Mr. David P. Hochman
Founder, Chairman of the Board of Directors & Chief Executive Officer
Mr. Darren R. Sherman
Founder, President, Chief Operating Officer & Director
Mr. William Reed Little
Executive Vice President of Corporate Development & Strategy